ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of Genes and the Environment in Patients With Prostate Cancer Residing in the East Anglia, Trent, or West Midlands Regions of the United Kingdom

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00758173
Recruitment Status : Unknown
Verified September 2008 by National Cancer Institute (NCI).
Recruitment status was:  Recruiting
First Posted : September 23, 2008
Last Update Posted : August 26, 2013
Sponsor:
Information provided by:
National Cancer Institute (NCI)

September 22, 2008
September 23, 2008
August 26, 2013
February 2008
Not Provided
  • Acquisition of epidemiological information and biological material
  • Identification of novel cancer susceptibility genes
  • Estimation of the age and sex-specific risks associated with variants in predisposition genes
  • Evaluation interactions between polymorphisms in predisposition genes and potential lifestyle risk factors
Same as current
Complete list of historical versions of study NCT00758173 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Study of Genes and the Environment in Patients With Prostate Cancer Residing in the East Anglia, Trent, or West Midlands Regions of the United Kingdom
A Population Based Study of Genetic Predisposition and Gene-Environment Interactions in Prostate Cancer in East Anglia, Trent and West Midlands

RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.

PURPOSE: This study is looking at genetic susceptibility and the interactions between genes and the environment in patients with prostate cancer.

OBJECTIVES:

  • To obtain epidemiological information and biological material on a population-based series of prostate cancer cases.
  • To identify novel cancer susceptibility genes by comparison of genotype frequencies in cases with the corresponding frequencies in large control series.
  • To estimate the age and sex-specific risks associated with variants in predisposition genes.
  • To evaluate interactions between polymorphisms in predisposition genes and potential lifestyle risk factors.

OUTLINE: This is a multicenter study.

Patients complete a detailed epidemiological questionnaire, including information on education, occupation, smoking habits, alcohol consumption, height, weight, family history of cancer, and past medical history.

Blood samples are collected from patients. DNA is extracted from these blood samples and from samples collected from cancer-free control participants in MREC-SEARCH-CONTROL as well as from additional controls through the European Prospective Investigation of Cancer (EPIC) study (a population based study of diet and health based in Norfolk, East Anglia). DNA samples are analyzed for polymorphisms of low penetrance cancer susceptibility genes.

In addition to the prostate cancer patients recruited for this study, patients with breast, ovarian, endometrial, colorectal, bladder, kidney, pancreatic, brain and esophageal cancer, malignant melanoma, and lymphoma cancer are recruited in the following related clinical trials: MREC-SEARCH-BREAST, MREC-SEARCH-OVARIAN, MREC-SEARCH-ENDOMETRIAL, MREC-SEARCH-COLORECTAL, and MREC-SEARCH-CANCER.

Observational
Not Provided
Not Provided
Not Provided
Not Provided
Not Provided
Prostate Cancer
  • Genetic: polymorphism analysis
  • Other: laboratory biomarker analysis
  • Other: questionnaire administration
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Unknown status
2000
Same as current
Not Provided
Not Provided

DISEASE CHARACTERISTICS:

  • Diagnosis of prostate cancer within the past 5 years
  • Identified through the cancer registry serving any of the following geographic regions of the United Kingdom:

    • East Anglia
    • Trent
    • West Midlands

PATIENT CHARACTERISTICS:

  • Identified by the patient's general practitioner as fit to contact for this study
  • No serious mental illness or retardation

PRIOR CONCURRENT THERAPY:

  • Not specified
Sexes Eligible for Study: Male
18 Years to 74 Years   (Adult, Older Adult)
No
Contact information is only displayed when the study is recruiting subjects
United Kingdom
 
 
NCT00758173
CDR0000589199
MREC-SEARCH-PROSTATE
Not Provided
Not Provided
Not Provided
Not Provided
Cancer Research UK
Not Provided
Study Chair: Paul Pharoah, MD Cancer Research UK
National Cancer Institute (NCI)
September 2008